Preclinical safety assessment of pathogen reduced red blood cells treated with amustaline and glutathione
Sign Up to like & getrecommendations! Published in 2020 at "Transfusion"
DOI: 10.1111/trf.15662
Abstract: The nucleic acid targeted pathogen reduction (PR) system utilizing amustaline (S‐303) and glutathione (GSH) is designed to inactivate blood‐borne pathogens and leukocytes in red blood cell concentrates (PR‐RBCC). Inactivation is attained after amustaline intercalates and… read more here.
Keywords: red blood; pathogen; preclinical safety; blood ... See more keywords